Crowdfunding gene therapy, when it works

The choice this guide compares

Crowdfunding closes a fraction of one-time gene-therapy budgets; success correlates with a clear medical story, an early local-press anchor, and a credible custody plan for the funds. This guide is written for patients and families evaluating two or more concrete options, not for general orientation; the assumption is that you already know the drug, the indication and the destination country, and you are deciding between paths.

What each option optimises for

Each option in this comparison optimises for a different dimension. One optimises for cost; one for speed; one for clinical proximity; one for paperwork cleanliness. There is no globally dominant option. The right choice is the one that aligns the optimisation dimension with the patient's actual constraint, which is usually time, money or clinician access, in that order.

Cost comparison

On a like-for-like basis, options differ by 30-300 percent on total all-in cost, not on drug cost alone. The drug is often the smaller variable; cold-chain handling, customs, broker and local hospital fees stack up, and a US-route specialty pharmacy with an integrated logistics partner often beats a fragmented multi-operator stack on total cost, even when the drug-line price looks higher.

Speed comparison

Direct manufacturer compassionate-use supply, where granted, is the fastest path: the manufacturer ships within days of approval. Named-patient via a specialty pharmacy is the next fastest, typically 14-30 days. Clinical-trial enrollment, when the drug is free, is the slowest to start but the cleanest cost; eligibility windows and protocol screening dominate the timeline.

Safety comparison

Provenance, not pathway, drives safety. Any of these options is safe when chain-of-custody is documented end-to-end, when the pharmacy is licensed, and when the treating physician administers the drug per protocol. Any of these options is unsafe when those conditions are missing. The pathway is not the variable; the operator is.

Documentation comparison

Direct manufacturer supply carries the lightest documentation burden on the patient because the manufacturer owns most of the file. Specialty pharmacy is medium; the patient or operator builds the documentation. Hospital-led procurement is heaviest on documentation but cleanest on customs and on local-regulator standing.

When each option wins

Direct manufacturer wins when the patient is in a compassionate-use eligible cohort and the manufacturer is supplying that cohort. Specialty pharmacy wins for cash-pay patients in liberal personal-import jurisdictions where the drug is shelf-stable. Hospital-led wins for cold-chain biologics, REMS drugs, and any jurisdiction that requires hospital-pharmacy receipt by law.

When to combine

Many patient files end up combining options: a clinical trial for the long-term supply, a specialty-pharmacy named-patient procurement for the bridging dose while the trial enrolls, and a hospital-led import for the in-country administration. The combination is more expensive than any single path but is often the right risk-adjusted answer.

How Reserve Meds positions in this comparison

Reserve Meds is positioned as a US-sourced cross-border specialty-pharmacy concierge. We do not compete with manufacturer compassionate use; we layer underneath it as a bridging procurement when the manufacturer pathway is too slow or not granted. We do not compete with clinical trials; we sometimes coordinate procurements that bridge to trial enrollment. We do compete with fragmented multi-operator stacks, and our claim there is simpler: one operator, one quote, one chain-of-custody, one US-licensed pharmacist sign-off.

Frequently asked questions

Which option is fastest?

Direct manufacturer compassionate-use supply is fastest when granted; named-patient procurement via a specialty pharmacy is second; clinical trials are slowest to enroll but fastest in cost.

Which option is safest?

Provenance, not pathway, is what determines safety; any pathway with full DSCSA chain-of-custody and treating-physician administration is acceptable.

Can I switch operators mid-process?

Yes, but pricing and lead-time reset; documents transfer only with the patient's written consent.

Related on Reserve Meds

• Drug catalog
• Conditions
• Access pathways
• Countries
• Access guides
• How to choose between operators
• Getting a second operator quote

Sources

• EMA - Medicines
• U.S. Food and Drug Administration - Drugs
• OECD - Pharmaceutical pricing policies
• FDA - Drugs at FDA

Start a request

Start a request